ATE171073T1 - Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine - Google Patents
Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteineInfo
- Publication number
- ATE171073T1 ATE171073T1 AT93923685T AT93923685T ATE171073T1 AT E171073 T1 ATE171073 T1 AT E171073T1 AT 93923685 T AT93923685 T AT 93923685T AT 93923685 T AT93923685 T AT 93923685T AT E171073 T1 ATE171073 T1 AT E171073T1
- Authority
- AT
- Austria
- Prior art keywords
- plasminogen
- pharmaceutical composition
- liposomes
- site
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Actuator (AREA)
- Structures Of Non-Positive Displacement Pumps (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9201722A NL9201722A (nl) | 1992-10-05 | 1992-10-05 | Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE171073T1 true ATE171073T1 (de) | 1998-10-15 |
Family
ID=19861342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93923685T ATE171073T1 (de) | 1992-10-05 | 1993-10-05 | Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0662841B1 (de) |
| JP (1) | JPH08502060A (de) |
| AT (1) | ATE171073T1 (de) |
| AU (1) | AU5345494A (de) |
| CA (1) | CA2146324A1 (de) |
| DE (1) | DE69321131D1 (de) |
| NL (1) | NL9201722A (de) |
| NO (1) | NO951219L (de) |
| WO (1) | WO1994007537A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| DE19529223A1 (de) * | 1995-08-09 | 1997-02-13 | Boehringer Mannheim Gmbh | Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau |
| KR102897177B1 (ko) * | 2019-04-12 | 2025-12-05 | 유지엘엑스 리서치 에이비 | 장기 복구를 위한 방법 및 장치 |
| EP3952644B1 (de) * | 2019-04-12 | 2025-09-24 | UGLK Science AB | Verfahren und vorrichtung zur rekonditionierung von nieren |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE831867A (fr) * | 1975-07-29 | 1976-01-29 | Association d'un activateur du plasminogene, d'une part, et du plasminogene lui-meme | |
| JPS52102975A (en) * | 1976-02-24 | 1977-08-29 | Toyota Motor Corp | Hydraulic driving system |
| US4193983A (en) * | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
| DE3682754D1 (de) * | 1985-12-16 | 1992-01-16 | Ethicon Inc | Hemmung von post-chirurgischer adhaesionsbildung durch topische verabreichung von gewebeplasminogenaktivator. |
| US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
| JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
-
1992
- 1992-10-05 NL NL9201722A patent/NL9201722A/nl not_active Application Discontinuation
-
1993
- 1993-10-05 WO PCT/NL1993/000195 patent/WO1994007537A1/en not_active Ceased
- 1993-10-05 CA CA002146324A patent/CA2146324A1/en not_active Abandoned
- 1993-10-05 JP JP6508918A patent/JPH08502060A/ja active Pending
- 1993-10-05 EP EP93923685A patent/EP0662841B1/de not_active Expired - Lifetime
- 1993-10-05 AT AT93923685T patent/ATE171073T1/de active
- 1993-10-05 DE DE69321131T patent/DE69321131D1/de not_active Expired - Lifetime
- 1993-10-05 AU AU53454/94A patent/AU5345494A/en not_active Abandoned
-
1995
- 1995-03-30 NO NO951219A patent/NO951219L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU5345494A (en) | 1994-04-26 |
| CA2146324A1 (en) | 1994-04-14 |
| NO951219L (no) | 1995-06-06 |
| EP0662841B1 (de) | 1998-09-16 |
| JPH08502060A (ja) | 1996-03-05 |
| NO951219D0 (no) | 1995-03-30 |
| DE69321131D1 (de) | 1998-10-22 |
| EP0662841A1 (de) | 1995-07-19 |
| WO1994007537A1 (en) | 1994-04-14 |
| NL9201722A (nl) | 1994-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6355243B1 (en) | Method of thrombolysis by local delivery of active plasmin | |
| Giles et al. | A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo | |
| Broze | Binding of human factor VII and VIIa to monocytes. | |
| DE69323195T2 (de) | VERKÜRZTER GEWEBSFAKTOR UND FVIIa ODER FVII ZUR AKTIVIERUNG DER BLUTGERINNUNG | |
| Monroe et al. | Platelet activity of high‐dose factor VIIa is independent of tissue factor | |
| EP0968008B1 (de) | Stabilisierte mischung auf fibrinogenbasis | |
| CN1182879C (zh) | 一种含纤维蛋白原的稳定化混合物 | |
| EP0333740B1 (de) | Pharmazeutisch aktive konjugate mit spezifität für die bindung an körpergewebe | |
| CA2200394A1 (en) | A pharmaceutical preparation for treating blood coagulation disorders | |
| ATE279430T1 (de) | Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen | |
| Levin et al. | Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells | |
| Hedner et al. | Clinical Experience with Human Plasma-Derived Factor VIla in Patients with Hemophilia A and High Titer Inhibitors | |
| ES2183805T3 (es) | Procedimiento de preparacion de un medicamento trombolitico. | |
| DK0477274T3 (da) | Faktor Xa baserede antikoaguleringspræparater | |
| Bishop et al. | Comparison of recombinant human thrombin and plasma-derived human α-thrombin | |
| JP2820699B2 (ja) | 血栓溶解剤 | |
| US5023078A (en) | Plasminogen activator-heparin conjugates | |
| Swenson et al. | α-Fibrinogenases | |
| US20030175264A1 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| DE69321131D1 (de) | Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine | |
| Wintroub et al. | Cleavage of fibrinogen by the human neutrophil neutral peptide-generating protease. | |
| de Serrano et al. | Influence of various structural domains of fibrinogen and fibrin on the potentiation of plasminogen activation by recombinant tissue plasminogen activator | |
| US5091363A (en) | Agent for the therapy of factor viii-resistant hemophilia a, and a process for the preparation thereof | |
| EP0253582A1 (de) | Modifizierter Gewebsplasminogenaktivator | |
| Bachmann | Fibrinolytic agents |